TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis
Pharmaceutics · 25.06.2024 · 16 (7) · 857
DOI: 10.3390/pharmaceutics16070857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 25.06.2024. Verfasst von Anna-Polina S Shurygina und 9 weiteren Autor:innen. Beteiligte Einrichtung: Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health of the Russian Federation, Saint Petersburg State Research Institute of Phthisiopulmonology within the framework of the State Task of the Ministry of Health of the Russian Federation.
Abstract (Originalsprache)
The steady rise of drug-resistant tuberculosis (TB), which renders standard therapy regimens ineffective, necessitates the development of innovative treatment approaches. Immunotherapeutic vaccines have the potential to effectively regulate the anti-TB immune response and enhance the efficacy of anti-TB treatment. In the present study, we aimed to evaluate the potency of the mucosal vector vaccine TB/FLU-06E as part of a complex treatment regimen for drug-susceptible (DS) or drug-resistant (DR) tuberculosis in C57BL/6 mice. Incorporating TB/FLU-06E into the treatment protocol significantly increased the effectiveness of therapy for both forms of tuberculosis. It was evidenced by higher survival rates and reduced pulmonary bacterial load (1.83 lg CFU for DS tuberculosis and 0.93 lg CFU for DR tuberculosis). Furthermore, the treatment reduced pathomorphological lesions in the lungs and stimulated the local and systemic T-helper 1 (Th1) and cytotoxic T-lymphocyte (CTL) anti-TB immune responses. Thus, therapeutic immunization with the TB/FLU-06E vaccine significantly enhances the efficacy of tuberculosis treatment, which is particularly important in DR tuberculosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Smorodintsev Research Institute of Influenza, The Ministry of Health of the Russian Federation, 197022 Saint-Petersburg, Russia.
- Saint-Petersburg State Research Institute of Phthisiopulmonology, The Ministry of Health of the Russian Federation, 194064 Saint-Petersburg, Russia.
ORCID-Profile: Anna-Polina S Shurygina, Dmitriy A Lioznov
Förderung
- Ministry of Health of the Russian Federation
- Saint Petersburg State Research Institute of Phthisiopulmonology within the framework of the State Task of the Ministry of Health of the Russian Federation
Zitieren
APA
Shurygina, A. S., Zabolotnykh, N. V., Vinogradova, T. I., Vitovskaya, M. L., Dogonadze, M. Z., Vasilyev, K. A., Buzitskaya, Z. V., Yablonskiy, P. K., Lioznov, D. A., & Stukova, M. A. (2024). TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis. Pharmaceutics, 16(7), 857. https://doi.org/10.3390/pharmaceutics16070857
Vancouver
Shurygina AS, Zabolotnykh NV, Vinogradova TI, Vitovskaya ML, Dogonadze MZ, Vasilyev KA, et al. TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis. Pharmaceutics. 2024;16(7):857. doi:10.3390/pharmaceutics16070857
BibTeX
@article{Shurygina2024,
author = {Shurygina, Anna-Polina S and Zabolotnykh, Natalia V and Vinogradova, Tatiana I and Vitovskaya, Maria L and Dogonadze, Marine Z and Vasilyev, Kirill A and Buzitskaya, Zhanna V and Yablonskiy, Petr K and Lioznov, Dmitriy A and Stukova, Marina A},
title = {TB/FLU-06E Influenza Vector-Based Vaccine in the Complex Therapy of Drug-Susceptible and Drug-Resistant Experimental Tuberculosis},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {7},
pages = {857},
doi = {10.3390/pharmaceutics16070857}
}
EUVIMED